💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Verteporfin

CHEMBL5314346 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Verteporfin is a benzoporphyrin derivative photosensitizing agent that accumulates preferentially in abnormal neovascular endothelium and, when activated by non-thermal red light (689 nm), generates reactive oxygen species that damage vascular endothelium, causing selective occlusion of abnormal blood vessels. It is FDA-approved for photodynamic therapy (PDT) of neovascular age-related macular degeneration, pathological myopia, and ocular histoplasmosis. It has also been investigated for its Hippo pathway inhibitory effects (YAP inhibition) in cancer.

ด้านการรักษา

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Age-Related Macular Degeneration Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

กลไกการออกฤทธิ์

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Verteporfin is a benzoporphyrin derivative photosensitizing agent that accumulates preferentially in abnormal neovascular endothelium and, when activated by non-thermal red light (689 nm), generates reactive oxygen species that damage vascular endothelium, causing selective occlusion of abnormal blood vessels. It is FDA-approved for photodynamic therapy (PDT) of neovascular age-related macular degeneration, pathological myopia, and ocular histoplasmosis. It has also been investigated for its Hippo pathway inhibitory effects (YAP inhibition) in cancer.

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Yes, Verteporfin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314346. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.